The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib with chemotherapy for EGFR-mutant NSCLC at progression: Safety profile and survival analysis.
 
Joel W. Neal
Consulting or Advisory Role - ARIAD/Takeda; AstraZeneca; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Loxo
Research Funding - ARIAD/Takeda (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst)
 
Daniel Hausrath
No Relationships to Disclose
 
Heather A. Wakelee
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - AstraZeneca
Research Funding - ACEA Biosciences (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Kristen Cunanan
No Relationships to Disclose
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; HERON; Lilly; Pfizer; Regeneron; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Clovis Oncology; Corvus Pharmaceuticals; Esanex; Genentech/Roche; Lilly; Lycera; Merck; Molecular Partners; OncoMed; Pfizer; Threshold Pharmaceuticals
 
Mandeep Banwait
No Relationships to Disclose
 
Lecia V. Sequist
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Merrimack; Pfizer
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Genentech (Inst); Guardant Health (Inst); Incyte (Inst); Johnson & Johnson (Inst); Loxo (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst)
 
Kevin Stirling
No Relationships to Disclose
 
Zofia Piotrowska
Consulting or Advisory Role - Abbvie; ARIAD/Takeda; AstraZeneca; Guardant Health; Immunogen; Immunogen; Novartis; Spectrum Pharmaceuticals
Research Funding - ARIAD/Takeda (Inst); AstraZeneca (Inst); Guardant Health (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ARIAD/Takeda; AstraZeneca